Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG

NCT06501495 | Recruiting

• 1 other identifier: APHP240231
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

With age, memory processes (encoding, consolidation and retrieval) as well as daytime vigilance are altered. Sleep is also impaired in older adults, notably slow waves that are known to play a key role in memory consolidation. Interestingly, some slow waves can also be detected in EEG recordings during wakefulness, and have been related to vigilance fluctuations. The investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves could thus explain the impact of aging on the different memory processes. Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory. The investigators will examine the associations between slow waves and changes in memory and vigilance in normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients with prodromal AD. By replaying sensory cues associated with learning material during sleep, the investigators will also evaluate the effectiveness of auditory stimulation during sleep to enhance memory consolidation in older adults without and without cognitive deficits. Overall, this study aims to better understand the relationships between slow waves, aging, memory, and vigilance, providing insights into cognitive decline and potential interventions in aging and Alzheimer's disease.

Conditions

Aging; Alzheimer Disease

Keywords

aging; Alzheimer's disease; sleep; memory; attention; slow

Outcome Measures

Primary Outcomes (1)

• slow waves density

  quantifying slow waves with their density (during sleep, wakefulness at rest and during tasks)

  2 days

Study Arms (1)

young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease

EXPERIMENTAL

young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease

Other: video polysomnography; Other: Attention task

Interventions

video polysomnography OTHER

video polysomnography during 2 nights

young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease

Attention task OTHER

Attention task : SART Test (Sustained Attention to Response Task)

young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female Signed informed consent Affiliated with a social security system Native French speakers Completed at least 7 years of schooling (minimum 9th grade level)
• Patients:
• Age: 60 to 85 years Prodromal stage of Alzheimer's disease diagnosed according to international diagnostic criteria, characterized by a clinical phenotype of progressive amnesic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease 1) from lumbar puncture (Aβ \< 600 pg/mL and ptau \> 60 pg/mL)or 2) amyloid PET (positron emission tomography), or 3) with positive plasma Alzheimer's biomarkers
• Cognitively Healthy Seniors:
• Age: 60 to 85 years Age and sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test
• Young Adults:
• Age: 18 to 35 years Sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Maladies du Sommeil

Paris, 75013, France

RECRUITING

Related Links

• Project article on the funder's website (Fondation France Alzheimer)

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Officials

• Marc Teichmann, MD

  assisitance publique Hôpitaux de paris

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marc Teichmann, MD

CONTACT

01 42 16 75 34; marc.teichmann@aphp.fr

Pierre Champetier, PhD

CONTACT

06 83 92 02 39; pierre.champetier@icm-institute.org

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 1, 2024
• First Posted: July 15, 2024
• Study Start: April 24, 2025
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): April 1, 2027
• Last Updated: April 13, 2026

Record last verified: 2026-04

Locations

FR (1)